Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Extracellular vesicles derived from adipose-derived mesenchymal stem/stromal cells prevent synovial inflammation and attenuate cartilage degeneration in rodent osteoarthritis.

Maruiwa Y., Niki Y., Mabuchi Y., Takeuchi O., Kuronuma S., Fukuda Y.

Animal Study on Osteoarthritis, Cartilage Damage, Chronic Inflammation, Immune Modulation, published in Regen Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Regen Ther (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41551961
PMCID
PMC12809275
DOI
10.1016/j.reth.2025.101056

Abstract (original English)

Objective Osteoarthritis (OA) is the most common joint disease in the elderly and a major cause of pain and disability. Recent advances in OA therapy have led to a greater variety of treatment options. Extracellular vesicles (EVs) have recently emerged as a potential therapeutic approach for OA. This study aimed to demonstrate the disease-modifying effects of adipose-derived mesenchymal stem cell-derived EVs (MSC-EVs) on OA. Methods The anti-inflammatory effects of MSC-EVs were evaluated using RAW264.7 macrophage-like cells stimulated with lipopolysaccharide and human synovial cells stimulated with IL-1β. In vivo, MSC-EVs were administered intra-articularly into knees of rats with monosodium iodoacetate (MIA)-induced OA. Pain thresholds, gait parameters, histological scores, and cytokine levels were assessed. Single-cell RNA sequencing (scRNA-seq) was performed on joint tissues to evaluate cell-specific gene expression and macrophage polarization. Results In vitro, MSC-EVs reduced the mRNA expression of IL-1β and IL-6 in RAW264.7 cells, and significantly suppressed multiple inflammatory cytokines while upregulating FGF-18 in synovial cells. In vivo, intra-articular MSC-EV injection increased pain threshold, improved gait, and reduced synovial inflammation and cartilage degeneration. scRNA-seq revealed decreased inflammatory cytokines, increased PRG4 and FGF-18 expression, and a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research